造血干细胞基因编辑与基因治疗:从底层技术开发到临床转化
- 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020
- 2 天津医学健康研究院,天津 301600
摘要
Therapeutic gene editing and gene therapy of hematopoietic stem cell: from underlying technology development to clinical translation
- 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
- 2 Tianjin Institutes of Health Science, Tianjin 301600, China
Abstract
Hematopoietic stem cells (HSC) possess self-renewal capacity and multilineage differentiation potential, rendering them ideal vehicles for gene therapy. Gene editing technologies exemplified by clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) have advanced rapidly, propelling HSC-based gene therapy from basic research to clinical practice and offering hope for the radical cure of hereditary hematological disorders such as 茁-thalassemia and sickle cell disease. This review systematically summarizes the developmental context and latest advances in HSC gene editing, as well as novel breakthroughs in delivery systems and in vivo therapy;synthesizes preclinical evidence and translational challenges in key hematological disease models; and outlines the efficacy and safety profiles of approved therapies and pivotal clinical trials. Despite lingering challenges in editing precision, delivery efficiency, long-term safety, and treatment accessibility, the development of novel editing and delivery systems, the aid of artificial intelligence, and the progress of global clinical collaboration are driving HSC-based gene therapy toward an era of safer, more efficient, and accessible precision cure.
